Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Thalidomide capsules	TA228 - Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Thalidomide		GAVE in renal disease
Thiopental injection
Thiotepa injection		For hospital use only
Tildrakizumab	TA575 - Tildrakizumab for treating moderate to severe plaque psoriasis
Tioguanine tablets
Tisagenlecleucel (Kymriah®)	TA554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years TA567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tisseel		Hospital use only
Tivozanib	TA512 - Tivozanib for treating advanced renal cell carcinoma
Tobradex eye drops

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.